Neuro-Oncology Reviews




Volume 27 Number 15
31 May 2025




Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 15, 31 May






Barańska K, Niemas K, Pełka K, Kunikowska J.
PET/CT in the Imaging of CNS Tumors.
Semin Nucl Med. 2025 May 21:S0001-2998(25)00040-6. doi: 10.1053/j.semnuclmed.2025.04.002. PMID: 40404539. Review˰ ˍ




Beylerli O, Gareev I, Kaprin A, Ahmad A, Chekhonin V, Yang S, Yang G.
Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.
Cancer Gene Ther. 2025 May 21. doi: 10.1038/s41417-025-00914-8. PMID: 40394233. Review˰ ˍ




Elliott WJ, Gurramkonda N, Guda MR, Tsung AJ, Velpula KK.
Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme.
Cells. 2025 May 21;14(10):755. doi: 10.3390/cells14100755. PMID: 40422257. Review. ˍ




Expert Panel on Neurological Imaging; Ivanidze J, Shih RY, Utukuri PS, Ajam AA, Auron M, Chang SM, Jordan JT, Kalnins A, Kuo PH, Ledbetter LN, Pannell JS, Pollock JM, Sheehan J, Soares BP, Soderlund KA, Wang LL, Burns J.
ACR Appropriateness Criteria® Brain Tumors.

J Am Coll Radiol. 2025 May 21;22(5S):S108-S135. doi: 10.1016/j.jacr.2025.02.036. PMID: 40409872. Guidelines. ˍ




Sun Y, Wang Y, Mu S, Wu X, Yu S, Wang Z.
Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges.
Front Oncol. 2025 May 22;15:1523675. doi: 10.3389/fonc.2025.1523675. PMID: 40475019. Review. ˍ




Williams A, Neth B, Webb M, Schwartz J, Daniels D, Caron S, Campian J, Uhm J, Ida C, Breen WG, Raghunathan A, Sener U.
Diffuse hemispheric glioma, H3 G34-mutant: defining the clinical picture through a single institution case series and literature analysis.
J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05028-7. PMID: 40402198. Case report; Review˰ ˍ




Zhang L, Tang G, Sun X, Xiao X, Ma F.
Assisted reproductive technology and risk of malignancy among offspring: a meta-analysis.
Int J Surg. 2025 May 22. doi: 10.1097/JS9.0000000000002554. PMID: 40405863. Meta-analysis. ˍ




Fredricks N, Price A, Jonzzon S, D'Souza P, Wellons JC, Ramaswamy V, Dewan MC.
Surgical management of recurrent medulloblastoma: a scoping review.
J Neurosurg Pediatr. 2025 May 23:1-7. doi: 10.3171/2025.2.PEDS2534. PMID: 40408881. Review˰ ˍ




Lee C, Lee J, Jeong M, Nam D, Rhee I.
Emerging strategies for targeting tumor-associated macrophages in glioblastoma: A focus on chemotaxis blockade.
Life Sci. 2025 May 24;376:123762. doi: 10.1016/j.lfs.2025.123762. PMID: 40419107. Review˰ ˍ




Chen Y, Ding K, Zheng S, Gao S, Xu X, Wu H, Zhou F, Wang Y, Xu J, Wang C, Ling C, Xu J, Wang L, Wu Q, Giamas G, Chen G, Zhang J, Yi C, Ji J.
Post-translational modifications in DNA damage repair: mechanisms underlying temozolomide resistance in glioblastoma.
Oncogene. 2025 May 26;44(23):1781-1792. doi: 10.1038/s41388-025-03454-5. PMID: 40419791. Review. ˍ




Shankar V, Harshil Sai V, Cholayil S.
Letter to the Editor Regarding "Metformin as an Adjunct Treatment to Temozolomide for High-Grade Gliomas: A Systematic Review and Meta-Analysis".
World Neurosurg. 2025 May 26;199:124121. doi: 10.1016/j.wneu.2025.124121. PMID: 40436336. Letter. ˍ
RELATED ARTICLE
Bittencurt Thomaz de Assis E, Ferreira MY, Sales de Oliveira J, Mitre LP, Correa da Silva EM, Salim Coelho LL, Moreno DA, Polverini AD.
Metformin as an Adjunct Treatment to Temozolomide for High-Grade Gliomas: A Systematic Review and Meta-Analysis.
World Neurosurg. 2025 Feb 27;197:123842. doi: 10.1016/j.wneu.2025.123842. PMID: 40023279. Review; Meta-Analysis. ˍ




Wu W, Xie Y, Jiang C, Jiang X.
Unveiling the multifaceted functions of TRIM proteins in glioma pathogenesis.
Transl Oncol. 2025 May 26;58:102419. doi: 10.1016/j.tranon.2025.102419. PMID: 40424933. Review. ˍ




Mojica CV, Gutierrez KME, Mason WP.
Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.
Future Oncol. 2025 May 27:1-11. doi: 10.1080/14796694.2025.2511587. PMID: 40424199. Review˰ ˍ




Mahboubi E, Mondanizadeh M, Almasi-Hashiani A, Ghasemi E.
Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review.
Eur J Med Res. 2025 May 28;30(1):425. doi: 10.1186/s40001-025-02674-5. PMID: 40437615. Review. ˍ




Aghedi M, Larijani A, Bagheri AB, Rafiemanesh H, Saraee E, Mardi S, Shirani M.
Efficacy of combined therapy with gamma knife radiosurgery and bevacizumab on survival outcomes in patients with recurrent high-grade glioma: a systematic review and meta-analysis.
Neurosurg Rev. 2025 May 29;48(1):459. doi: 10.1007/s10143-025-03632-9. PMID: 40439764. Review; Meta-Analysis. ˍ




Kusaczuk M, Piskorz WM, Domasik J.
Marizomib in the therapy of brain tumors-how far did we go and where do we stand?
Pharmacol Rep. 2025 May 29. doi: 10.1007/s43440-025-00739-0. PMID: 40439869. Review. ˍ




Baptista JM, Brenner LBO, Henrique A, Ito LA, Nabarro PH, Santos LP, Palavani LB, Berbet LU, Koga JV, Salvarani CP, Nespoli VS, Bertani R.
Efficacy and safety of intraoperative magnetic resonance imaging for low-grade and high-grade gliomas: an updated systematic review and meta-analysis.
Neurosurg Rev. 2025 May 30;48(1):465. doi: 10.1007/s10143-025-03631-w. PMID: 40445417. Review; Meta-Analysis˰ ˍ




Tomaselli A, Luca A, Ferini G, Umana GE, Chaurasia B, Scalia G.
Cognitive Profiles and Determinants of Eligibility for Awake Surgery in Non-Dominant Hemisphere Gliomas: A Narrative Review.
Brain Behav. 2025 May 30;15(6):e70604. doi: 10.1002/brb3.70604. PMID: 40444665. Review. ˍ




Wang M, Wang Z, Zhang G, Fan J.
Interleukin-enhanced CAR-engineered immune cells in tumor immunotherapy: current insights and future perspectives.
Cytokine. 2025 May 30;192:156973. doi: 10.1016/j.cyto.2025.156973. PMID: 40449036. Review˰ ˍ




Xuan F, Lv T, Zheng L, Yu S, Ding M.
Analysis of the correlation between inflammatory cytokines and glioblastoma: A Mendelian randomization study.
Medicine (Baltimore). 2025 May 30;104(22):e42137. doi: 10.1097/MD.0000000000042137. PMID: 40441232. Meta-Analysis. ˍ




Bao J, Pan Z, Wei S.
Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas.
Discov Oncol. 2025 May 31;16(1):971. doi: 10.1007/s12672-025-02815-6. PMID: 40448901. Review. ˍ